Blog

The mental health medication landscape is unique, but our solution always finds the savings opportunities—including this massive one.

Whatever the next normal looks like, and whenever we get there, our goal is still the same: make the world a better place for our members and clients.

The rush to recommend an unproven drug for COVID-19 led to shortages or unnecessary expense for patients who actually benefit from it. Once again, our solution and support team stepped up.

We may be working from 150 different home offices right now, but a quick visit to six of them illustrates how all our teams come together to help members during this pandemic—and all the time.

We caught a big price hike for the active ingredient in hydroxycholorquine, hailed by some as an effective COVID-19 treatment. Whatever the outcome on tablet prices, our solution is already helping affected members.

In a time when consumers and companies are under great financial stress, here's an example of how we help our members and our clients save precious dollars. We're talking thousands every fill!

There's no telling what our technology would look like today if not for a winter storm in 2013. Here's what happened when our CTO met our founder and CEO, each armed with a snow shovel.

Is it possible to LOVE any employee benefit? We have plenty of evidence that Rx Savings Solutions members do. We see it through volumes of member survey feedback and consistently high Net Promoter Scores.

How many privacy policies or terms of disclosure have you agreed to lately? How many have you read? Here's what happens to the personal and health information of Rx Savings Solutions members—and, more importantly, what doesn’t.

January is a tumultuous time for pharmacy consumers. It can be downright depressing. We can’t make spring arrive any sooner, but we can shed light on their plan year changes and offer a ray of sunshine to members who need it.

Can you measure the state of the economy using only one indicator? Of course not. The White House called us out on our drug prices analysis. Here's our response.